Author:
KASHIMA Naotaka,ISHIHARA Junichi,TAZAWA Hiroki,NOGUCHI Hisashi,HIRAIZUMI Takashi,HORICHI Naoya,SATO Ikuyo,OHMORI Tohru,OHNISHI Tsukasa,KASAHARA Keita,YAMAMOTO Masato,NAKAJIMA Hiroaki,TAKAHASHI Terumi,SASAKI Yasutsuna
Publisher
The Showa University Society
Reference10 articles.
1. 1) Costanzi JJ, Gangliano R, Loukas D, Frank J, Panettiere J and Hokanson A: Ifosfamide in the treatment of recurrent or disseminated lung cancer. A phase II study of two dose schedules. Cancer, 41: 1715-1719 (1978)
2. 2) Costanzi JJ, Mogan LR and Hokanson JA: Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semiri Oncol, 9 (suppl 1) : 61-65 (1982)
3. 3) Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Morgan LR, Plotokin D, Tucker WG and Worrall PM: Single dose ifosfamide: effigy studies in non-small cell lung cancer. Semin Oncol, 9 (suppl 1) : 56-60 (1982)
4. 4) Morgan LR, Posey LE, Rainey J, Bickers J, Ryan D, Vial R, Hull EW et al: Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep, 65: 693-695 (1981)
5. 5) Nobile MT, Rosso R and Brema F: Phase II study of ifosfamide combined with mesna uroprotection in advanced non-small cell carcoinoma and other solid tumors. Tumori, 70: 433-437 (1984)